Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Haynes, B.; Gilbert, P.; McElrath, M.; Zolla-Pazner, S.; Tomaras, G.; Alam, S.; T. Evans, David; Montefiori, D.; Karnasuta, C.; Sutthent, R.; Liao, H.; Devico, A.; Lewis, G.; Williams, C.; Pinter, A.; Fong, Youyi; Janes, H.; C. deCamp, Allan; Huang, Yunda; Rao, M.; Billings, E.; Karasavvas, N.; Robb, M.; Ngauy, V.; de Souza, M.; Paris, R.; Ferrari, G.; Bailer, R.; Soderberg, K.; Andrews, C.; Berman, P.; Frahm, N.; C. De Rosa, Stephen; Alpert, M.; L. Yates, Nicole; Shen, Xiaoying; Koup, R.; Pitisuttithum, P.; Kaewkungwal, J.; Nitayaphan, S.; Rerks-Ngarm, S.; Michael, N.; H. Kim, Jerome

doi:10.1056/NEJMoa1113425

Public

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Shared by NobleBlocks on Apr 4, 2012 • 12:00 AM UTC

Authors:

B. Haynes

P. Gilbert

M. McElrath

Abstract

BACKGROUND In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to identify antibody and cellular immune correlates of infection risk. METHODS In pilot studies conducted with RV144 blood sa...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!